BRAF and colonic neoplasm: A cohort of 53 patients with actionable lesions was identified via in-house panel sequencing (n = 34) or, especially in patients with colon cancer, by targeted sequencing of hotspot regions (such as BRAF) as well as testing for microsatellite stability or PDL-1 expression (n = 19) (Fig. 2).